Effect of co-administered dalteparin sodium and alteplase on clinical and biochemical parameters in postpartum patients with lower extremity deep venous thrombosis

Abstract

Purpose: To investigate the clinical efficacy of co-administration of dalteparin sodium and alteplase in the treatment of postpartum lower extremity deep venous thrombosis.Methods: A total of 88 patients with postpartum lower extremity deep venous thrombosis admitted to Jiangxi Provincial People's Hospital of The First Affiliated Hospital of Nanchang Medical College, Nanchang, China from January 2020 to December 2022 were enrolled in this study and divided into study group (treated with dalteparin sodium and alteplase) and control group (treated with alteplase only), with 44 patients in each group. Clinical parameters (limb circumference, pigmentation and ulcer area), hemorheological parameters [D-Dimer (D_D), fibrinogen (FIB), centipoise (CP), red cell assembling index (RCAI)], inflammatory factors (hs-CRP, IL-6, THF-a, NMP-9) and cell adhesion factors {platelet endothelial cell adhesion molecule-1 (PECAM-1) and vascular cell adhesion molecule 1 (VCAM-1)} were determined and recorded.Results: Post-treatment, all the clinical and biochemical parameters in the study group were significantly improved compared with pre-treatment levels and the respective levels in the control group (p < 0.05). The overall response rate (ORR) in the study group was 95.45 %, which was higher than the 79.55 % for the control group (p < 0.05).Conclusion: Concomitant administration of dalteparin sodium and alteplase is more efficacious than treatment of with alteplase alone in the management of postpartum lower extremity deep venous thrombosis. However, further clinical trials on this combination therapy is required for the validation of findings obtained in this work.